Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3409
$0.00341.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.00K | 43.00K | 74.00K | 80.00K | 449.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.00K | 43.00K | 74.00K | 80.00K | 449.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 14.00K | 43.00K | 74.00K | 80.00K | 449.00K |
| SG&A Expenses | 8.03M | 5.41M | 6.34M | 6.72M | 6.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.70M | 12.05M | 15.61M | 20.28M | 22.94M |
| Operating Income | -12.69M | -12.00M | -15.54M | -20.20M | -22.49M |
| Income Before Tax | -7.78M | -11.99M | -15.83M | -20.36M | -22.73M |
| Income Tax Expenses | 572.00K | -782.00K | -2.40M | -2.86M | -3.03M |
| Earnings from Continuing Operations | -8.35 | -11.21 | -13.43 | -17.51 | -19.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.35M | -11.21M | -13.43M | -17.51M | -19.70M |
| EBIT | -12.69M | -12.00M | -15.54M | -20.20M | -22.49M |
| EBITDA | -12.68M | -12.00M | -15.52M | -20.19M | -22.46M |
| EPS Basic | -48.71 | -85.02 | -179.42 | -280.33 | -356.59 |
| Normalized Basic EPS | -32.65 | -65.54 | -130.19 | -199.61 | -251.40 |
| EPS Diluted | -48.71 | -85.02 | -179.42 | -280.33 | -356.59 |
| Normalized Diluted EPS | -32.65 | -65.54 | -130.19 | -199.61 | -251.40 |
| Average Basic Shares Outstanding | 13.78M | 906.10K | 381.80K | 300.00K | 239.50K |
| Average Diluted Shares Outstanding | 13.78M | 906.10K | 381.80K | 300.00K | 239.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -0.37% | -0.57% | -0.77% |